Ionis Price Targets Cut After Trial Miss, September 8 2026
Three healthcare names drew eight analyst actions on Tuesday, the first session after the Labor Day break. Ionis took five of them, Amgen two and BioNTech one. One desk downgraded twice. Six target figures came down and not one was raised. Ionis Books $268 Million In Quarterly Revenue And Draws Five Analyst Actions Ionis makes...
Read articleTrending topics
Lululemon Price Targets Cut By Three Desks, September 4 2026
Three companies reported after the close on Thursday and drew thirty-four analyst actions across Friday. Zscaler took fifteen of them, Lululemon twelve and Asana seven. Twenty-two carried a new price target figure. Lululemon Books $2.4 Billion In Quarterly Revenue And Draws Twelve Analyst Actions Lululemon sells athletic apparel under its own name. It sells through...
Read article
Ultragenyx Downgraded, Price Targets Cut, September 3 2026
Ten analyst actions landed on Thursday. Ultragenyx ($RARE) drew five of them after a failed trial readout. Snowflake ($SNOW) drew three and CrowdStrike ($CRWD) two. Ultragenyx Books $214 Million In Quarterly Revenue And Draws Five Analyst Actions Ultragenyx develops treatments for rare genetic diseases. Crysvita, for X-linked hypophosphatemia, is its largest product. Dojolvi, Evkeeza and...
Read article